Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 9

Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod

Authors Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C

Published Date March 2013 Volume 2013:9 Pages 73—85


Received 12 September 2012, Accepted 16 November 2012, Published 3 March 2013

Claudio Gasperini,1 Serena Ruggieri,2 Chiara Rosa Mancinelli,2 Carlo Pozzilli2

1Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy; 2Department of Neurology and Psychiatry, Sapienza – University of Rome, Rome, Italy

Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs for MS in Europe, and two second-line treatments. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different side effects. Despite disease-modifying drugs being well known and safe, they require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Therefore, the development of new therapeutic strategies is warranted. Several oral compounds are in late stages of development for treating MS. Fingolimod is an oral sphingosine-1-phosphate receptor modulator that has demonstrated superior efficacy compared with placebo and interferon β-1a in phase III studies. It has already been approved in the treatment of MS. This review focuses on advances in current and novel oral treatment approaches in MS. We summarily review the oral compounds in this study, focusing on the recent development, approval, and the clinical experience with fingolimod.

Keywords: multiple sclerosis, oral compounds, fingolimod, sphingosine-1-phosphate, patient satisfaction, adherence

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets

Claudio Gasperini, Serena Ruggieri, Carlo Pozzilli

Therapeutics and Clinical Risk Management 2010, 6:391-399

Published Date: 31 August 2010

Readers of this article also read:

Case of femoral diaphyseal stress fracture after long-term risedronate administration diagnosed by iliac bone biopsy

Nagai T, Sakamoto K, Ishikawa K, Saito E, Kuroda T, Inagaki K

Therapeutics and Clinical Risk Management 2013, 9:191-195

Published Date: 30 April 2013

Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac

Peniston JH, Gold MS, Wieman MS, Alwine LK

Therapeutics and Clinical Risk Management 2013, 9:153-159

Published Date: 16 April 2013

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod

Hanson KA, Agashivala N, Stringer SM, Balantac Z, Brandes DW

Patient Preference and Adherence 2013, 7:309-318

Published Date: 16 April 2013

Diagnosis and management of miliary tuberculosis: current state and future perspectives

Ray S, Talukdar A, Kundu S, Khanra D, Sonthalia N

Therapeutics and Clinical Risk Management 2013, 9:9-26

Published Date: 8 January 2013